血液透析联合血液灌流治疗方案对透析并发高磷血症患者的疗效探讨

The Therapeutic Effect of Hemodialysis Combined with Hemoperfusion on Patients with Hyperphosphatemia Complicated by Dialysis

目的探究血液透析联合血液灌流治疗方案对透析并发高磷血症患者的临床疗效。方法择选该院2019年1月—2020年1月收治的尿毒症高磷血症患者50例为研究对象,由计算机系统按随机分组原则,均分为对照组(单一血液透析治疗)和研究组(血液透析联合血液灌流治疗)两组。治疗后,分别就血清尿素氮、肌酐、血钙等指标在两组患者中实施对比,并对比两组患者心血管疾病发生情况。结果治疗后,研究组患者的P(1.75±0.51)mmol/L、iPTH(258.12±27.71)ng/L优于对照组的(2.33±0.47)mmol/L和(287.22±28.15)ng/L,差异有统计学意义(t=4.181、3.683,P<0.05)。研究组患者心血管疾病发生率4%远低于对照组的24%,差异有统计学意义(χ^(2)=4.152,P<0.05)。结论血液透析联合血液灌流治疗方案对透析并发高磷血症患者疗效显著,可有效降低相关指标,避免心血管疾病风险,具有较高的应用价值。

Objective To explore the clinical efficacy of hemodialysis combined with hemoperfusion therapy in patients with dialysis complicated by hyperphosphatemia.Methods Fifty patients with uremia and hyperphosphatemia admitted to the hospital from January 2019 to January 2020 were selected as the research objects.The computer system was randomly divided into the control group(single hemodialysis treatment)and study group(hemodialysis combined with hemoperfusion therapy).After treatment,serum urea nitrogen,creatinine,blood calcium and other indicators were compared between the two groups of patients,and the incidence of cardiovascular disease in the two groups was compared.Results After treatment,the P(1.75±0.51)mmol/L and iPTH(258.12±27.71)ng/L of the study group were better than those of the control group(2.33±0.47)mmol/L and(287.22±28.15)ng/L,the difference was statistically significant(t=4.181,3.683,P<0.05).At the same time,the incidence of cardiovascular disease in the study group was 4%,which was far lower than the 24% in the control group,and the difference was statistically significant(χ^(2)=4.152,P<0.05).Conclusion Hemodialysis combined with hemoperfusion therapy has a significant effect on patients with dialysis complicated by hyperphosphatemia.It can effectively reduce the relevant indicators and avoid the risk of cardiovascular disease.It has high application value.